We also further demonstrated the clinical feasibility of detecting FLT3 expression in CML specimens via immunoblotting, immunofluorescence, or PCR methods, as well as targeting FLT3+ CML cells with approved FLT3 inhibitors. The gene discussed is FLT3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.